Search ARM

Archived Publications & Presentations


February 7th 2019

DIA Europe 2019 - How to Facilitate Access to ATMPs in Europe

Vienna, Austria

January 23rd 2019

Phacilitate: Leaders World

Miami, Florida

January 7th 2019

2019 State of the Industry Briefing

San Francisco, CA

November 15th 2018

Bipartisan Policy Center Roundtable on Gene Therapy for Neurodegenerative Disease

Washington, DC

October 26th 2018

American Thrombosis and Hemostasis Network Data Summit

Chicago, IL

October 18th 2018

BIA UK Bioscience Forum 2018

London, UK

September 5th 2018

State of the Industry Update - Cell & Gene Therapy: Bioprocessing & Commercialization

Boston, MA

September 4th 2018

Cell & Gene Connect: Evolving Landscape of Cell & Gene Therapies

Boston, MA

May 22nd 2018

Alliance for Regenerative Medicine Policy Lunch

Washington, DC

March 1st 2018

ARM Advanced Therapies Summit


January 1st 2018

ARM 2018 Cell & Gene Therapy State of the Industry

JP Morgan Biotech Showcase, San Francisco

November 1st 2017

ARM European Investor Day



In Vivo Article

Moving From Chronic Therapies To Cures – Creating A Pathway To Enable New Payment Models

July 23rd 2018

ARM Position Paper

Position on possible solutions to foster development and expand patient access for Advanced Therapy Medicinal Products in Europe

March 14th 2018

Journal of Managed Care Medicine

Ensuring Patient Access to Regenerative and Advanced Therapies in Managed Care: How Do We Get There?

January 1st 2018

ARM Position Paper

Possible solutions to improve the European regulatory procedures for clinical trials with Advanced Therapy Medicinal Products consisting of or containing Genetically Modified Organisms

September 1st 2017


June 13th 2018

RMAT Designation – Impact on Regenerative Medicine Sector

Gain a deeper understanding of the implications of the Regenerative Medicine Advanced Therapies (RMAT) designation and the significance of its support and advancement by the FDA in this webinar recording. Held in partnership with the Alliance for Regenerative Medicine (ARM), ARM, Informa Pharma Intelligence, and representative from Abeona, Athersys, and Enzyvant discuss the RMAT designation and its implications on the sector.

May 9th 2018

NTAP and the Next Generation of Cures

Michael Werner, Co-Founder and Senior Policy Counsel for ARM, and Robert Falb, Director of U.S. Policy and Advocacy, participated in BIO’s webinar on NTAP and advanced therapies on May 9. ARM believes that it is critical that the NTAP program be modernized to facilitate patient access to new and life-saving treatments.

October 24th 2017

CAR-T Approval: What’s Next?

CAR-T cell therapy is now approved in the U.S. The first product, Novartis’ Kymriah, is approved to treat pediatric and young adult patients with B-cell acute lymphoblastic lymphoma, and products for other oncological indications are hot on its heels. Join Informa Pharma Intelligence and ARM for an interactive webinar to explore what this historic approval means for the patient community, as well as how this sector will approach the scientific, clinical, policy and business issues surrounding CAR-T approvals.

Submitted Comments, Letters, Statements

February 2019

December 2018

October 2018

September 2018

August 2018

July 2018

June 2018

March 2018

February 2018